PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Context: Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. Objective: We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve stenosis and myocardial infarction. Design: We used two prospective cohort studies of the general population and one patient-based cohort. Setting: Cohort studies selected at random individuals of Danish descent. Participants: We studied 103 083 individuals from the Copenhagen General Population Study, the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. Main outcome measures: Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals. Results: Median (interquartile range) lipoprotein(a) levels were 10 (5–30) mg/dl for PCSK9 R46L noncarriers, 9 (4–32) mg/dl for heterozygotes, and 8 (4–42) mg/dl for homozygotes (trend P = .02). The corresponding values for LDL cholesterol levels were 124 (101–147) mg/dl, 104 (85–132) mg/dl, and 97 (85–128) mg/dl, respectively (trend P = 2 × 10−52). PCSK9 R46L carriers vs noncarriers had an age- and sex-adjusted odds ratio of 0.64 (95% confidence interval, 0.44–0.95) for aortic valve stenosis, 0.77 (0.65–0.92) for myocardial infarction, and 0.76 (0.64–0.89) for aortic valve stenosis or myocardial infarction. Conclusions: PCSK9 R46L carriers have lower levels of lipoprotein(a) and LDL cholesterol as well as reduced risk of aortic valve stenosis and myocardial infarction. This indirectly suggests that PCSK9 inhibitors may have a role in patients with aortic valve stenosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 5×
“Specifically, the PCSK9 R46L loss-of-function mutation has been associated with lower levels of LDL cholesterol and with reduced risk of ischemic heart disease and MI (11, 13, 14).”
BackgroundResultInfluentialEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 2×
“However, PCSK9 inhibitor treatment has also been shown to lower lipoprotein(a) (15, 16).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 2×
“The Copenhagen City Heart Study is a prospective study of the general population initiated in 1976–1978 with follow-up examinations in 1981–1983, 1991–1994, and 2001–2003 (18).”
BackgroundSelf-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 2×
“Recently, however, several other risk factors similar to those for coronary artery disease have emerged and include smoking, high blood pressure, high cholesterol, diabetes, and male sex (25).”
BackgroundLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“A limitation of our study is that we included only white individuals of Danish descent and this may limit the applicability to other ethnicities, especially because lipoprotein(a) levels differ among different ethnic groups (6, 7, 27).”
BackgroundSelf-citation(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Research works printed but not linked: 1
- Utermann, 2001, Lipoprotein(a), 2753
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Gaba, P., O’Donoghue, M. L., Park, J.-G., Wiviott, S. D., Atar, D., Kuder, J. F., Im, K., Murphy, S. A., De Ferrari, G. M., Gaciong, Z. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063399 · Cited by 184
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Bergmark, B. A., O’Donoghue, M. L., Murphy, S. A., Kuder, J. F., Ezhov, M. V., Ceška, R., Gouni-Berthold, I., Jensen, H. K., Tokgozoglu, S. L., Mach, F., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0728 · Cited by 137
Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies
Larsson, S. C., Wolk, A., Håkansson, N., & Bäck, M. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx140 · Cited by 123
Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy
Zheng, K. H., Tzolos, E., & Dweck, M. R. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.010 · Cited by 134
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Perrot, N., Valerio, V., Moschetta, D., Boekholdt, S. M., Dina, C., Chen, H. Y., Abner, E., Martinsson, A., Manikpurage, H. D., Rigade, S., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.004 · Cited by 91
Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313864 · Cited by 85
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 86
Innate and adaptive immunity in cardiovascular calcification
Passos, L. S. A., Lupieri, A., BECKER-GREENE, D. R., & Aïkawa, E. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.016 · Cited by 85
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 76
The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Bernardi, S., Marcuzzi, A., Piscianz, E., Tommasini, A., & Fabris, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124058 · Cited by 77
“For example, PCKS9 inhibition reduces lipoprotein(a) (Lp(a)) [77,78], which is similar to LDL but more atherogenic.”
BackgroundLee, S. H., Kim, N., Kim, M., Woo, S.-H., Han, I., Park, J., Kim, K., Park, K. S., Kim, K., Shim, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33202-2 · Cited by 70
The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly
Pinese, M., Lacaze, P., Rath, E. M., Stone, A., Brion, M.-J., Ameur, A., Nagpal, S., Puttick, C., Husson, S., Degrave, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14079-0 · Cited by 70
Recent advances in demystifying the metabolism of lipoprotein(a)
Chemello, K., Chan, D. C., Lambert, G. C., & Watts, G. F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.002 · Cited by 70
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01058 · Cited by 67
“Lipoprotein(a) total mass was measured using apolipoprotein A isoform‒insensitive turbidimetric assays, either an in-house assay as described elsewhere (13), an assay from DiaSys (DiaSys Diagnostic Systems, Holzheim, Germany) or an assay from Denka Seiken (Denka Seiken, Tokyo, Japan).”
Self-citationNovel pharmacological targets for calcific aortic valve disease: Prevention and treatments
Myasoedova, V. A., Ravani, A. L., Frigerio, B., Valerio, V., Moschetta, D., Songia, P., & Poggio, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.020 · Cited by 62
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
Guo, Q., Feng, X., & Zhou, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.01020 · Cited by 56
Broeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 63
“Interestingly, a post hoc analysis of this trial displayed that treatment with evolocumab might also reduce CAVD related events [15], which is in line with the findings that patients with a PCSK9 loss-of-function mutation have a reduced CAVD risk [75].”
ResultLipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
“ing the make early diagnosis to prevent early deaths or Simon-Broome FH diagnostic criteria (77) as well as in”
BackgroundGene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 61
Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns
Erhart, G., Lamina, C., Lehtimäki, T. J., Marques-Vidal, P. M., Kähönen, M. A. P., Vollenweider, P., Raitakari, O. T., Waeber, G., Thorand, B., Strauch, K., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310865 · Cited by 61
“In line with the effects of PCSK9 inhibitors,(16) the PCSK9 LOF mutation R46L (rs11591147) with a minor allele frequency (MAF) of 3% was associated with ≈10% lower Lp(a) concentrations in a Danish population.(13) Lp(a) concentrations show pronounced interethnical differences.”
BackgroundInfluentialPCSK9 Involvement in Aortic Valve Calcification
Poggio, P., Songia, P., Cavallotti, L., Barbieri, S. S., Zanotti, I., Arsenault, B. J., Valerio, V., Ferri, N., Capoulade, R., & Camera, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.063 · Cited by 54
“Interestingly, high levels of PCSK9 have been previously shown to correlate also with the presence of calcific aortic valve stenosis (CAVS) (2) and an early study showed that carriers of the PCSK9 R46L loss-of-function genetic variant might have a low CAVS risk (3).”
BackgroundNelson, C. P., Lai, F. Y., Nath, M., Ye, S., Webb, T. R., Schunkert, H., & Samani, N. J. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002196 · Cited by 55
Lipoprotein(a) and calcific aortic valve stenosis: A systematic review
Guddeti, R. R., Patil, S., Ahmed, A., Sharma, A., Aboeata, A., Lavie, C. J., & Alla, V. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.06.002 · Cited by 55
Tang, Y., Li, S.-L., Hu, J.-H., Sun, K.-J., Liu, L.-L., & Xu, D.-Y. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01009-4 · Cited by 51
Romagnuolo, R., Scipione, C. A., Marcovina, S. M., Gemin, M., Seidah, N. G., Boffa, M. B., & Koschinsky, M. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180869 · Cited by 52
PCSK9 promotes arterial medial calcification
Lupo, M. G., Bressan, A., Donato, M., Canzano, P., Camera, M., Poggio, P., Greco, M. F., Garofalo, M., Martin, S. D., Panighel, G., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.015 · Cited by 45
The Pathophysiologic Basis and Management of Calcific Aortic Valve Stenosis
Desai, M. Y., & Braunwald, E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.049 · Cited by 44
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Phua, K., Chew, N., Kong, W. K. F., Tan, R., Ye, L., & Poh, K. K. (2022) · Theranostics · doi:10.7150/thno.71813 · Cited by 43
“Langsted A [77] 2016 Cohort study (n=103,083) PCSK9 loss-of-function mutation have lower levels of Lp(a) and reduced risk of AS”
BackgroundThe complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 42
Diamantopoulou, A., Sun, Z., Mukai, J., Xu, B., Fenelon, K., Karayiorgou, M., & Gogos, J. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615719114 · Cited by 41
“A well-established example is provided by studies of the PCSK9 locus, where therapeutic agents designed to inhibit PCSK9 were prospectively developed in response to the detected protective effects of PCSK9 LoF variants on LDL cholesterol levels and coronary artery disease risk (6, 7).”
BackgroundLipoprotein(a) and PCSK9 inhibition: clinical evidence
Ruscica, M., Greco, M. F., Ferri, N., & Corsini, A. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa135 · Cited by 38
“The corresponding levels of LDL-C were 124mg/dL, 104mg/dL and 97mg/dL, respectively.(20) Although existing PCSK9 inhibitors outcome trials did not enroll patients with high Lp(a), their use in ASCVD patients with high plasma Lp(a) corresponded to a higher number of subjects discontinuing LA.”
BackgroundAtherosclerosis Calcification: Focus on Lipoproteins
Neels, J. G., Lefthériotis, G., & Chinetti, G. (2023) · Metabolites · doi:10.3390/metabo13030457 · Cited by 47
“Patients with the PCSK9 loss of function mutation (PCSK9 R46L), characterized by decreased circulating Lp(a) and LDL-cholesterol, had reduced risk of calcific aortic stenosis [76].”
BackgroundLjungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 40
“The present study added important information regarding Lp(a) and the risk of AS.”
BackgroundInfluentialPCSK9: Associated with cardiac diseases and their risk factors?
Guo, Y., Yan, B., Tai, S., Zhou, S., & Zheng, X.-L. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108717 · Cited by 36
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 40
“Gain-of-function mutations in the PCSK9 gene have been linked to FH [193], while loss-of-function mutations are associated with lower LDL-C and Lp(a) levels, as well as reduced cardiovascular events and aortic stenosis [194,195].”
BackgroundNovel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 40
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 39
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 35
“, reporting that loss-of-function PCSK9 R46L carriers had lower levels of Lp(a) and a reduced risk of aortic valve stenosis compared to non-carriers [87].”
BackgroundEfficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 33
Blanchard, V., Chemello, K., Hollstein, T., Hong-Fong, C. C., Schumann, F., Grenkowitz, T., Nativel, B., Coassin, S., Croyal, M., Kassner, U., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab247 · Cited by 31
Zheng, K. H., Arsenault, B. J., Kaiser, Y., Khaw, K., Wareham, N. J., Stroes, E. S. G., & Boekholdt, S. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013020 · Cited by 32
“In addition, the PCSK9 R46L loss-of-function mutation is associated with reduced risk of AVS and myocardial infarction.(18) Recently, experimental data suggested that PCSK9 may also directly facilitate calcification in valvular interstitial cells.”
BackgroundRaitakari, O. T., Kivelä, A. M., Pahkala, K., Rovio, S., Mykkänen, J., Ahola‐Olli, A., Loo, B.-M., Lyytikäinen, L., Lehtimäki, T. J., Kähönen, M. A. P., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.009 · Cited by 35
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Verbeek, R., Boyer, M., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J. P., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307995 · Cited by 30
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 30
“Furthermore, Langsted et al. (2016) found that patients with a PCSK9 loss-of-function mutation (PCSK9 R46L) have lower serum LDL and Lp(a) levels and a lower risk of calcific aortic stenosis based on data from 103,083 people in the Copenhagen General Population Study [24].”
BackgroundInfluentialTargeting low‐density lipoprotein cholesterol with PCSK9 inhibitors
Scherer, D. J., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13451 · Cited by 29
Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis
Rämö, J. T., Jurgens, S. J., Kany, S., Choi, S. H., Wang, X., Smirnov, A. N., Friedman, S. F., Maddah, M., Khurshid, S., Ellinor, P. T., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070982 · Cited by 26
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Grejtáková, D., Boroňová, I., Bernasovská, J., & Bellosta, S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07599-5 · Cited by 25
“The application of results regarding the link among PCSK9, LDLR, and Lp(a) metabolism is questionable, especially since Lp(a) plasma levels differ among different ethnic groups [47–49].”
Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 22
Kritharides, L., Nordestgaard, B. G., Tybjærg‐Hansen, A., Kamstrup, P. R., & Afzal, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01049 · Cited by 21
Self-citationFu, B., Wang, J., Wang, L., Wang, Q., Guo, Z., Xu, M., & Jiang, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.944521 · Cited by 19
“Lipid-lowering therapy can reduce the morbidity and mortality associated with cardiovascular diseases (47).”
BackgroundLow cholesterol states: clinical implications and management
Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19
New Biological Therapies for Low-Density Lipoprotein Cholesterol
Gill, P. K., & Hegele, R. A. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.003 · Cited by 19
Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis
Trenkwalder, T., Nelson, C. P., Musameh, M. D., Mordi, I. R., Kessler, T., Pellegrini, C., Debiec, R., Rheude, T., Lazovic, V., Zeng, L., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.094 · Cited by 18
“Indeed, a loss of function mutation (R46L) in PCSK9 mimicking the effect of PCSK9 inhibitors have been found to be associated with lower Lp(a) level and reduced risk of AVS [25].”
BackgroundBosco, G., Barbagallo, F. D. G., Marco, M. D., Scilletta, S., Miano, N., Pistritto, C., Tiralongo, M., Stefano, C. D., Pennisi, G., Francesco, E. M. D., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07432-z · Cited by 18
“Conversely, carriers of PCSK9 loss-of-function (LOF) mutations reported a reduction of Lp(a) plasma levels and oxidized phospholipid-apoB (oxPL-apoB) as well as a greater number of apo(a) Krin-gle IV repeats compared with non-carriers [48, 49].”
Biomarkers as Prognostic Markers for Aortic Stenosis: A Review
Sarkar, A., Chowdhury, S., Kumar, A., Khan, B., Chowdhury, S., Gupta, R., Hajra, A., & Aronow, W. S. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.001 · Cited by 19
Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner, Ž. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0773-y · Cited by 18
Costanzo, A. D., Indolfi, C., Franzone, A., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914939 · Cited by 17
“The mechanism is related to the loss of PCSK9 function, which is why PCSK9-i can lead to a reduction in the incidence and progression of aortic stenosis [105].”
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.603910 · Cited by 17
Aortic valvular stenosis: Novel therapeutic strategies
Natorska, J., Kopytek, M., & Undas, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13527 · Cited by 17
PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
Mefford, M. T., Marcovina, S. M., Bittner, V., Cushman, M., Brown, T. M., Farkouh, M. E., Tsimikas, S., Monda, K. L., López, J. A. G., Muntner, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p119000173 · Cited by 17
“Median apo(a) KIV repeats (25th, 75th percentile) 23 (20, 26) 24 (21, 27) 0.”
BackgroundResultInfluentialDietary patterns, food groups, and incidence of aortic valve stenosis: A prospective cohort study
Larsson, S. C., Wolk, A., & Bäck, M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.007 · Cited by 16
Atherosclerosis, calcific aortic valve disease and mitral annular calcification: same or different?
Hafiane, A., Pisaturo, A., Favari, E., & Bortnick, A. E. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132741 · Cited by 14
Lipoprotein(a) and aortic valve stenosis: A casual or causal association?
Santangelo, G., Faggiano, A., Bernardi, N., Carugo, S., Giammanco, A., & Faggiano, P. M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.015 · Cited by 14
Khan, M. I., Zahir, R. S., Dominguez, A. C., & Romeo, F. J. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101543 · Cited by 15
Zheng, Y., Li, Q., Yang, Y., Yang, J., Liu, Z., Ma, X., & Wang, Z. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042112 · Cited by 13
“4,5 8 As a result, the most recent guidelines from the American College of Cardiology/American Heart Association for valve disease management do not recommend statin therapy for CAVS.”
Genetics of aortic valve disease
Ackah, R. L., Yasuhara, J., & Garg, V. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001028 · Cited by 14
PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
Pokrywka, G. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1436843 · Cited by 13
Coassin, S., Chemello, K., Khantalin, I., Forer, L., Döttelmayer, P., Schönherr, S., Grüneis, R., Chong-Hong-Fong, C., Nativel, B., Ramin‐Mangata, S., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003489 · Cited by 13
PCSK9 in Vascular Aging and Age-Related Diseases
Tan, D., Yang, X., Yang, J., Fan, G., & Xiong, G. (2025) · Aging and Disease · doi:10.14336/ad.2024.1713 · Cited by 15
Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants
El-Menyar, A. A., Khan, N. A., Almahmeed, W. A., Suwaidi, J. M. S. A., & Al-Thani, H. A. S. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.012 · Cited by 12
PCSK9 and LRP6: potential combination targets to prevent and reduce atherosclerosis
Desita, S. R., Hariftyani, A. S., Jannah, A. R., Setyobudi, A. K., & Oktaviono, Y. H. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0291 · Cited by 12
Qiao, M., Li, Y., Yang, Y., Pang, C.-X., Liu, Y., Bian, C., Wang, L., Chen, X., & Hong, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115047 · Cited by 11
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10
Myasoedova, V. A., Franchi, M., Giorgi, D. D., Bonomi, A., Valerio, V., Pirola, S., Andreani, N., Rusconi, V., Bertolini, F., Massaiu, I., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107737 · Cited by 11
Myeloid CCN3 protects against aortic valve calcification
Tu, P., Xu, Q., Zhou, X., Villa-Roel, N., Kumar, S., Dong, N., Jo, H., Ou, C., & Lin, Z. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01020-0 · Cited by 10
Quarta, S., Santarpino, G., Carluccio, M. A., Calabriso, N., Maffia, M., Siculella, L., Damiano, F., Madonna, R., & Massaro, M. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107210 · Cited by 10
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Hsieh, G., Rizk, T., Berman, A. N., Biery, D. W., & Blankstein, R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000901 · Cited by 11
“From a large cohort of Danish patients, PCSK9 loss of function mutation R46L was associated with lower levels of Lp(a) as well as reduced risk of CAVS [44].”
BackgroundTowards Personalized Therapy of Aortic Stenosis
Mazur, P. K., Kopytek, M., Ząbczyk, M., Undas, A., & Natorska, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121292 · Cited by 12
“[24] have reported that the PCSK9 loss-of-function mutation was associated with lower serum levels of LDL and Lp(a), and reduced CAS risk.”
BackgroundMateos, N., Gómez, M., Homar, A., García-Elías, A., Yáñez, L., Tajes, M., Balaguer, L. M., Blé, M., Cladellas, M., Roqueta, C., et al. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10138-4 · Cited by 9
Chong, T., Lan, N. S. R., Courtney, W., He, A., Strange, G. A., Playford, D. A., Dwivedi, G., Hillis, G. S., & Ihdayhid, A. R. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000528 · Cited by 9
“…genetically low levels of PCSK9 due to R46L loss-of-function mutations result in lower levels of Lp(a) and LDL cholesterol, and lower risk of AS. 89 The potential benefits of PCSK9 inhibitors in slowing AS progression in individuals with at least mild AS are currently being studied in RCTs…”
Mak, M. C. E., Gurung, R., & Foo, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814057 · Cited by 9
“Loss of function mutations in PCSK9 have been linked to reduced levels of LDL cholesterol and lower incidences of coronary heart disease [28–32].”
BackgroundAceña, Á., Peláez, J. A. F., Lázaro, A. M. P., Parra, E. G., González‐Lorenzo, Ó., Martínez‐Milla, J., Hernández‐González, I., Martín‐Mariscal, M. L., Castillo, M. L., Kallmeyer, A., et al. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10050-3 · Cited by 9
Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study
Arafa, A., Kato, Y., Kokubo, Y., Khairan, P., Matsumoto, C., Nakao, Y. M., Kataoka, Y., & Harada‐Shiba, M. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65437 · Cited by 9
“…drugs did not affect our results, it is worth mentioning that proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors, known to reduce the levels of LDL-C and Lp(a) 46) , were not among these drugs because they were not legalized in Japan during the baseline checkup period 47) .”
Mok, C. C., Ho, L. Y., Chan, K. L., Tse, S. M., & To, C. H. (2023) · Inflammation · doi:10.1007/s10753-023-01821-6 · Cited by 8
“Conversely, lossof-function PCSK9 mutations are associated with lower serum LDLc levels and marked reduction of risk of coronary heart disease [5, 6].”
BackgroundThe pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism
Liu, G., Yu, X., Cui, C., Li, X., Wang, T., Palade, P., Mehta, J. L., & Wang, X. (2025) · Acta Physiologica · doi:10.1111/apha.14272 · Cited by 8
“107,108 Perrot et al. found that PCSK9 expression was higher in the stenotic aortic valves of patients compared to those without CAVD.”
Fan, F. S. (2023) · Tumor Biology · doi:10.3233/tub-230007 · Cited by 8
Surma, S., Zembala, M. O., Okopień, B., & Banach, M. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200297 · Cited by 7
“Interestingly, genetically determined lower level of PCSK9 is associated with a decreased risk of AS (OR = 0.64; 95 % CI: 0.44 – 0.95) [26].”
BackgroundInfluentialJahangir, A., Sahra, S., & Krzyzak, M. (2021) · Cureus · doi:10.7759/cureus.16664 · Cited by 7
“A reduced incidence of myocardial infarction and even aortic valve stenosis was seen in these patients with lower PCSK9 expression [26].”
BackgroundLiu, S., Wan, J., Wang, D., Yang, Y., Fang, J., Luo, T., Liang, D., Hu, J., Hou, J., & Wang, P. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.007 · Cited by 7
Insights into the Inherited Basis of Valvular Heart Disease
Yu, M., & Bouatia‐Naji, N. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02041-6 · Cited by 7
Plasma Proteomic Biomarkers of Aortic Stenosis
Yang, T., Small, A. M., Dufresne, L., Peloso, G. M., Natarajan, P., Engert, J. C., & Thanassoulis, G. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.046 · Cited by 6
The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
Shi, S., Qin, Z., Liu, C., Zhao, Y., Bai, X., Sun, C., Xu, L. L., Cong, W., Yuan, X., Sun, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-03419-4 · Cited by 7
“PCSK9 is closely related to the occurrence of various cardiovascular diseases 27–29 .”
Agstam, S., Agarwal, T., Gupta, A., & Bansal, S. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.01.017 · Cited by 7
Current Management and Therapy of Severe Aortic Stenosis and Future Perspective
Takeji, Y., Tada, H., Taniguchi, T., Sakata, K., Kitai, T., Shirai, S., & Takamura, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22023 · Cited by 7
Metadata
- Authors
- Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R.
- Affiliations
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- The Copenhagen General Population Study (A.L., B.G.N., M.B., A.T.-H., P.R.K.), Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
- Corresponding author
- Kamstrup, Pia R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-24
- Volume
- 101
- Issue
- 9
- Pages
- 3281-3287
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2404696858
- Cited by
- 136
- References
- 33
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 8 · 2016: 1
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Sanofi
- Fresenius Medical Care North America
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, loss-of-function mutations, lipoprotein(a), LDL cholesterol, aortic stenosis, myocardial infarction, PCSK9 inhibitors, genetic association, cardiovascular risk, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease prevention, Danish population, Copenhagen General Population Study, Copenhagen City Heart Study
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Genotype, Heterozygote, Humans, Cholesterol, LDL, Male, Middle Aged, Mutation, Myocardial Infarction, Prognosis, Prospective Studies, Risk Factors, Biomarkers, Lipoprotein(a), Genetic Predisposition to Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.